Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Lp(a) blood test may reveal hidden heart risks

NCT ID NCT07184034

Knowledge-focused Sponsor: Assiut University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 2 times

Summary

This observational study will check if levels of a fatty substance called lipoprotein(a) in the blood are linked to calcium buildup in heart arteries. About 150 adults at intermediate heart risk will get a CT scan and a blood test. The goal is to see if Lp(a) can help detect early heart disease better than standard risk factors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 150 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2025

An estimate. Start dates often move.

Expected to finish

Oct 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population will include adult men and women aged 40 to 70 years who are classified as having intermediate cardiovascular risk (10-20% estimated 10-year ASCVD risk). Participants will be those referred for non-contrast multi-slice CT (MSCT) for suspected coronary artery disease and who are able to provide informed consent. Patients will be excluded if they have known coronary artery disease, prior myocardial infarction, prior coronary revascularization, or history of stroke. Additional exclusions include recent use of statins or PCSK9 inhibitors within the past 3 months, renal insufficiency (eGFR \<45 mL/min/1.73m²), or active inflammatory or autoimmune disease.

Ages

30 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * 1-adults aged 40-70 * 2- classified as intermediate cardiovascular risk (10-20% 10 years ASCVD risk) * 3-undergoing MsCT for suspected coronary artery disease * 4- ability to provide informed consent Exclusion Criteria: * 1- known CAD or prior revascularization * 2-history of myocardial infarction or stroke * 3- statin or PCK9 inhibitor use in the past 3 months * 4-renal insufficiency (eGFR \< 45ml/min/1.73m2) * 5-active inflammation or autoimmune disease

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Coronary artery disease (CAD) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

coronary artery disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Coronary artery disease (CAD)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.